Clinical trials: High-Risk Cancer, open to volunteers
Multiple Myeloma, Cancer
Discontinuation Study
An interventional, non-randomised study to assess the risk of progression after discontinuation of maintenance therapy in sustained MRD negative complete remission by flow cytometry MM patients without high-risk features who have…
- Conditions
- Multiple Myeloma, Cancer, Hematologic Cancer
- Trial name
- NCT05866757
- Testing
- Discontinuation of maintenance treatment
- Where
- Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Advanced Cancer, Demoralization
MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial
This pilot clinical trial will study psilocybin-assisted therapy for adults with advanced cancer who are experiencing demoralization, existential distress, or related psychological concerns.
- Conditions
- Advanced Cancer, Demoralization, Existential Distress, Psychological Distress
- Trial name
- PAT-MIND (NCT07791901)
- Testing
- PEX010 25 mg psilocybin, PEX010 5 mg psilocybin, Standard Psilocybin-Assisted Therapy
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- University of Calgary
Carcinoma, Squamous Cell of Head and Neck HNSCC
Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial
The goal of this Phase 2 clinical trial is to learn if adding ruxolitinib to pembrolizumab may improve treatment outcomes in patients with head and neck squamous cell carcinoma (HNSCC) who have increased levels of systemic…
- Trial name
- InflammaSTOP (NCT07840456)
- Testing
- Ruxolitinib, Pembrolizumab
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 66 people
- Sponsor
- University Hospital, Basel, Switzerland
Hodgkin Lymphoma
Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma
This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment.
- Trial name
- NCT07222345
- Testing
- High Intensity Interval Training (HIIT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- St. Jude Children's Research Hospital
Colorectal Cancer
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection.
- Trial name
- NCT06515821
- Testing
- ONCOSCREEN
- Where
- 8 sites in Bulgaria, France and 4 more
- Volunteers
- 4,100 people
- Sponsor
- Firalis SA
Cutaneous Lymphoma
FLASH Pilot Phase 1 Safety Study
The primary purpose of this research trial is to study the safety of electron FLASH treatment for cutaneous lymphoma lesions. In addition, investigators will confirm the accuracy of dose and dose rate delivery of electron FLASH…
- Trial name
- NCT07608549
- Testing
- IntraOp Mobetron UHDR, Linac
- Volunteers
- 10 people
- Sponsor
- Lesley A. Jarvis
Hepatocellular Carcinoma
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
- Trial name
- NCT05489289
- Testing
- AK104
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Akeso
Sarcoma,Soft Tissue
Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)
Soft tissue sarcomas (STSs) are rare cancers with a 5-year survival rate of 60%, and there is no standard treatment for high-risk extremity and trunk STSs (eSTS).
- Trial name
- TNT-HYPE (NCT06835049)
- Testing
- Doxorubicin, Ifosfamide, Dacarbazine
- Where
- 8 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Swiss Cancer Institute
Ovarian Cancer
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
Ovarian Cancer (OC) is one of the most common gynecological malignant tumors. In recent years, the incidence of ovarian cancer in China has been on the rise, but its mortality ranks the first among gynecological tumors.
- Trial name
- NCT07125391
- Testing
- Propranolol Hydrochloride, Paclitaxel liposome, Carboplatin
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Bai-Rong Xia
Multiple Myeloma, Smoldering Multiple Myeloma
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or…
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
- Trial name
- NCT06768489
- Testing
- JNJ-79635322, Daratumumab, Pomalidomide
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 276 people
- Sponsor
- Janssen Research & Development, LLC
Colorectal Cancer, Mismatch Repair-deficient (dMMR)
Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
Colorectal cancer of Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) accounts for approximately 15% of all colorectal cancer patients, with a higher proportion in right colon cancer.
- Conditions
- Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
- Trial name
- PICC (NCT03926338)
- Testing
- Neoadjuvant toripalimab plus celecoxib for 6 cycles, Neoadjuvant toripalimab monotherapy for 6 cycles, Neoadjuvant toripalimab plus celecoxib for 12 cycles
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Sun Yat-sen University
Nasopharynx Cancer
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
This research aims to assess both effectiveness and safety of combining R-GEP regimen comprising gemcitabine, recombinant human endostatin, and cerexinib with low- and high-dose radiotherapy in managing unresectable recurrent…
- Trial name
- NCT06611826
- Testing
- GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy
- Volunteers
- 41 people
- Sponsor
- Zhejiang Cancer Hospital
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
This is a a phase III, randomized, open-label clinical trial comparing endocrine therapy combined with high-dose palbociclib and hydroxychloroquine to endocrine therapy combined with standard-dose palbociclib for hormone…
- Trial name
- NCT07061717
- Testing
- Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd, Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid, Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer, Pancreas Cancer
Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
The U-TRANS study was initiated by Gustave Roussy, which is its sponsor*. It is part of the Interception Program and aims to reduce the consumption of ultra-processed foods in order to improve the overall quality of the diet…
- Conditions
- Breast Cancer, Pancreas Cancer, Colon Cancer, Lynch Syndrome
- Trial name
- U-TRANS (NCT07436312)
- Testing
- educational workshop on nutrition + additional intervention on UPF tool and how to use it
- Where
- 3 sites in France
- Volunteers
- 170 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Solid Tumors With High Expression of Nectin4
Clinical Study of 68Ga-labeled Novel Nectin-4 Bicyclic Peptide PET/CT for Imaging of Solid Tumors With High Nectin-4 Expression
Tumors are one of the major diseases threatening human health, among which solid tumors account for a considerable proportion. Nectin-4, as an important cell adhesion molecule, shows a highly expressed state in various solid…
- Trial name
- NCT07319130
- Testing
- Immunohistochemistry
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
This phase II/III trial tests adding glofitamab to standard of care chemoimmunotherapy in patients with Burkitt and high grade (double hit) B- cell lymphomas that are newly diagnosed, that has come back after a period of…
- Conditions
- Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- Trial name
- NCT07724457
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Carboplatin
- Volunteers
- 271 people
- Sponsor
- National Cancer Institute (NCI)
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer.
- Trial name
- NCT06130995
- Testing
- Relugolix and Enzalutamide
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Oklahoma
Bone Cancer Metastatic
A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy
The objective of this study is to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in patients treated with both percutaneous ablation and palliative…
- Trial name
- TRIBUTE (NCT06859801)
- Testing
- Percutaneous Ablation, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 120 people
- Sponsor
- Society of Interventional Oncology
Prostate Cancer, Locally Recurrent Cancer
Study on Prostate Salvage Using High-dose-rate Brachytherapy
A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and…
- Conditions
- Prostate Cancer, Locally Recurrent Cancer, Biochemically Recurrent Prostate Carcinoma, Toxicity Radiation
- Trial name
- PROSCATE (NCT07860528)
- Where
- 10 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
AML, MDS
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days
- Trial name
- PIVOT (NCT06717958)
- Testing
- Ivosidenib 250 MG (milligram)
- Where
- 17 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Technische Universität Dresden